Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

Authors

  • Tai Hato,

    1. Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    Search for more papers by this author
  • Lipika Goyal,

    1. Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA
    Search for more papers by this author
  • Tim F. Greten,

    1. Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, Bethesda, MD
    Search for more papers by this author
  • Dan G. Duda,

    Corresponding author
    1. Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • Address reprint requests to: Dan G. Duda, DMD, Ph.D., Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114. Tel: 617-726-4648; E-mail: gduda@partners.org; fax: 617-726-1962; or Andrew X. Zhu, M.D., Ph.D., Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114. Tel: 617-643-3415; E-mail: azhu@partners.org; fax: 617-724-3116.

    Search for more papers by this author
  • Andrew X. Zhu

    Corresponding author
    1. Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA
    • Address reprint requests to: Dan G. Duda, DMD, Ph.D., Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114. Tel: 617-726-4648; E-mail: gduda@partners.org; fax: 617-726-1962; or Andrew X. Zhu, M.D., Ph.D., Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114. Tel: 617-643-3415; E-mail: azhu@partners.org; fax: 617-724-3116.

    Search for more papers by this author

  • Potential conflict of interest: Dr. Zhu consults for Sanofi-Aventis, Eisai, Exelixis, and Celgene.

  • Supported by National Institutes of Health grants P01-CA080124, R01-CA159258, and R21-CA139168, a National Cancer Institute/Proton Beam Federal Share Program award, and the American Cancer Society grant 120733-RSG-11-073-01-TBG (to D.G.D.); and a Postdoctoral Fellowship from Astellas Foundation for Research on Metabolic Disorders, Japan (to T.H.).

Abstract

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives. (Hepatology 2014;60:1776–1782)

Ancillary